Page updated ·next FDA decision on the calendar·Data as of Oct 14, 2026 7:39 PM ET
Price into the decision (T-120)
Daily close, T-120 (11/18/24) through T+5. Run-up high $22.77 on 1/3/25, low $12.82 on 4/11/25 (T-120 to T-1). FDA decision 5/5/25. Historical price action, not a forecast.
Positioning before the decision
On Apr 21, 2025, 14 days before the decision date, at-the-money options priced a move of ±13.2% through May 9, 2025 (the first listed expiry after the decision; ATM implied volatility 74%). The stock closed +1.2% at the first close across the decision and +4.6% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was SELARSDI (ustekinumab-aekn) injection approved by the FDA?
Yes. The FDA approved the application for SELARSDI (ustekinumab-aekn) injection on April 30, 2025, per the FDA's own record. The company announced it on May 5, 2025. The primary source is linked on this page.
What was SELARSDI (ustekinumab-aekn) injection under FDA review for?
The application covered Adults and pediatric psoriatic arthritis and plaque psoriasis. The FDA approved the application on May 5, 2025.
How did TEVA stock react to the FDA decision?
On the decision day TEVA moved +1.2%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.